452 Eli Lilly and Company $LLY Shares Purchased by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,940 shares of the company’s stock after acquiring an additional 452 shares during the period. YHB Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $11,501,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company during the second quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after buying an additional 400,538 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a report on Thursday, September 17th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, UBS Group set a $1,376.00 target price on Eli Lilly and Company in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside based on expectations for continued earnings and pipeline growth.
• Positive Sentiment: Obesity pipeline remains a major catalyst: Analysts point to retatrutide, Lilly’s next-generation triple-hormone weight-loss candidate, as a potential successor to Mounjaro and Zepbound. Its reported clinical weight-loss results and potential applications in related conditions could expand Lilly’s long-term addressable market. Eli Lilly’s Obesity Business Could Become a Much Bigger Healthcare Platform
• Positive Sentiment: Pipeline diversification continues: Lilly is testing eloralintide in an obesity-related study involving hormonal contraception and has initiated an early-stage Alzheimer’s trial. These studies are preliminary, but they reinforce the company’s efforts to build growth beyond its current GLP-1 franchise. Eli Lilly Tests Obesity Drug Eloralintide With Birth Control
• Positive Sentiment: Oncology and technical support: Jaypirca, Inluriyo and Retevmo could help offset slowing Verzenio sales, while a move above the 50-day moving average is viewed by some technical analysts as a short-term bullish signal.
• Neutral Sentiment: Investor sentiment remains constructive: Commentary highlights Lilly’s “growth flywheel” from GLP-1 demand, manufacturing expansion, new indications and earnings growth. However, these are largely forward-looking investment opinions rather than new financial results.
• Negative Sentiment: Valuation and competition remain concerns: Lilly trades at a premium multiple, leaving the stock vulnerable to profit-taking if obesity-drug growth slows, pricing pressure increases or Novo Nordisk and other competitors gain share. LLY Stock Down 2% in 3 Months
• Negative Sentiment: New obesity guidelines could create uncertainty: The World Health Organization’s childhood-obesity recommendations may increase scrutiny of how weight-loss medicines are used in younger populations, potentially affecting future market expectations for Lilly and Novo Nordisk.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 3.1%

Eli Lilly and Company stock traded down $36.48 during mid-day trading on Thursday, reaching $1,152.23. The company’s stock had a trading volume of 1,736,679 shares, compared to its average volume of 2,967,456. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65. The business’s 50 day simple moving average is $1,173.51 and its 200 day simple moving average is $1,094.59. The company has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 38.67, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.